Cancer cells use CDC42 to release GLS1‐containing vesicles, boosting glutamine metabolism, and promoting M2 macrophage polarization. This process aids macrophage‐mediated angiogenesis and contributes to trastuzumab resistance in HER2‐positive gastric cancer. Here, ERBB2 is linked to cancer.